SUBSCRIBE: eNewsletter
The FDA announced October 3 approval of Descovy®, making it the second drug to receive indication for HIV pre-exposure prophylaxis.
A first-of-its-kind study found that among cirrhosis patients with and without HIV-coinfection, liver function improved >50% in each cohort.
What are the top 5 HIV/AIDS apps that both physicians and patients can use? Scroll through our new slideshow to find out.
The "new year" is now in full swing and new drugs are being approved each month; check out our slideshow to get up to date on 9 drugs approved in the first quarter for primary care.
PrEP can decrease risk of HIV transmission. It can also contribute to risky sexual behavior and STIs.
A 34-year-old man with a history of HIV says family members are exaggerating his symptoms but that the headache and double vision are bothersome.
This case study of 2 patients suggests that very early antiretroviral therapy is not enough to prevent formation of latent viral reservoirs and prevent HIV rebound on treatment discontinuation.
Here: a quick look at newly approved agents for primary care that will soon be coming your way.
A systematic approach may help more primary care clinicians identify men who have sex with men among their patients, which in turn could help them focus on patients in need of more frequent HIV testing and preventive services.
"What we need to do now is to help people with HIV realize the full potential of their much-extended life expectancy."
We've noticed that you're using an ad blocker
Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.
